Related references
Note: Only part of the references are listed.Small molecules and their impact in drug discovery: A perspective on the occasion of the 125th anniversary of the Bayer Chemical Research Laboratory
Hartmut Beck et al.
DRUG DISCOVERY TODAY (2022)
Hematopoietic PBX-interacting protein is a novel regulator of mammary epithelial cell differentiation
Anju Dwivedi et al.
FEBS JOURNAL (2022)
A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease
Yuefeng Wu et al.
LIFE-BASEL (2022)
Prolactin: The Third Hormone in Breast Cancer
Linda A. Schuler et al.
FRONTIERS IN ENDOCRINOLOGY (2022)
The Relevant Participation of Prolactin in the Genesis and Progression of Gynecological Cancers
Adrian Ramirez-de-Arellano et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Periplasmic synthesis and purification of the human prolactin antagonist Δ1-11-G129R-hPRL
Miriam F. Suzuki et al.
AMB EXPRESS (2021)
Bispecific Antibodies: From Research to Clinical Application
Jiabing Ma et al.
FRONTIERS IN IMMUNOLOGY (2021)
ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition
Mark G. Anderson et al.
BMC CANCER (2021)
Suppression of Breast Cancer by Small Molecules That Block the Prolactin Receptor
Dana C. Borcherding et al.
CANCERS (2021)
Crosstalk between PRLR and EGFR/HER2 Signaling Pathways in Breast Cancer
Raghuveer Kavarthapu et al.
CANCERS (2021)
Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice
Prasad Dandawate et al.
GASTROENTEROLOGY (2020)
A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer
Yuexian Zhou et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
Charlotte Lemech et al.
INVESTIGATIONAL NEW DRUGS (2020)
Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer
Hironobu Minami et al.
ANTICANCER RESEARCH (2020)
Preparation of a Growth Hormone Receptor/Prolactin Receptor Bispecific Antibody Antagonist Which Exhibited Anti-Cancer Activity
Xin Chen et al.
FRONTIERS IN PHARMACOLOGY (2020)
Development of therapeutic antibodies for the treatment of diseases
Ruei-Min Lu et al.
JOURNAL OF BIOMEDICAL SCIENCE (2020)
An in vivo half-life extended prolactin receptor antagonist can prevent STAT5 phosphorylation
Shengze Yu et al.
PLOS ONE (2019)
Naturally split intein Npu DnaE mediated rapid generation of bispecific IgG antibodies
Lei Han et al.
METHODS (2019)
Prolactin and its receptor as therapeutic targets in glioblastoma multiforme
Antonela Sofia Asad et al.
SCIENTIFIC REPORTS (2019)
Prolactin: The Bright and the Dark Side
Felicitas Lopez Vicchi et al.
ENDOCRINOLOGY (2017)
Development of a new anti-prolactin receptor (PRLR) antibody, F56, which can serve as a PRLR antagonist
Huanzhong Cui et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2017)
Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody-Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers
Marcus P. Kelly et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps
Reetobrata Basu et al.
HORMONES & CANCER (2017)
Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system
Lei Han et al.
SCIENTIFIC REPORTS (2017)
The Role of Prolactin in Bone Metastasis and Breast Cancer Cell-Mediated Osteoclast Differentiation
Ashley Sutherland et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
The Role of Prolactin in Bone Metastasis and Breast Cancer Cell-Mediated Osteoclast Differentiation
Ashley Sutherland et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Synergistic Activation of ERα by Estrogen and Prolactin in Breast Cancer Cells Requires Tyrosyl Phosphorylation of PAK1
Peter Oladimeji et al.
CANCER RESEARCH (2016)
Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer
Neeraj Agarwal et al.
ONCOLOGIST (2016)
Prolactin- and Testosterone-Induced Carboxypeptidase-D Correlates With Increased Nitrotyrosines and Ki67 in Prostate Cancer
Lynn N. Thomas et al.
PROSTATE (2015)
Targeting Protein-Protein Interaction by Small Molecules
Lingyan Jin et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54 (2014)
Discussion about Several Potential Drawbacks of PEGylated Therapeutic Proteins
Fan Zhang et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2014)
Prolactin signaling enhances colon cancer stemness by modulating Notch signaling in a Jak2-STAT3/ERK manner
Naveen K. Neradugomma et al.
CARCINOGENESIS (2014)
Prolactin Induces Apoptosis of Lactotropes in Female Rodents
Jimena Ferraris et al.
PLOS ONE (2014)
Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death
Yunfei Wen et al.
CELL REPORTS (2014)
Prolactin Activates ERα in the Absence of Ligand in Female Mammary Development and Carcinogenesis in Vivo
Kathleen A. O'Leary et al.
ENDOCRINOLOGY (2013)
Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
Jason S. Damiano et al.
MOLECULAR CANCER THERAPEUTICS (2013)
The Role of Prolactin Receptor in GH Signaling in Breast Cancer Cells
Jie Xu et al.
MOLECULAR ENDOCRINOLOGY (2013)
Induction of Multidrug Resistance Transporter ABCG2 by Prolactin in Human Breast Cancer Cells
Alex Man Lai Wu et al.
MOLECULAR PHARMACOLOGY (2013)
Autocrine prolactin: an emerging market for homegrown (prolactin) despite the imports
Senthil K. Muthuswamy
GENES & DEVELOPMENT (2012)
The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells
Lin Hou et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Characterizing the Impact of Renal Impairment on the Clinical Pharmacology of Biologics
Bernd Meibohm et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
The Prolactin Gene: A Paradigm of Tissue-Specific Gene Regulation with Complex Temporal Transcription Dynamics
K. Featherstone et al.
JOURNAL OF NEUROENDOCRINOLOGY (2012)
Growth Hormone Signaling in Human T47D Breast Cancer Cells: Potential Role for a Growth Hormone Receptor-Prolactin Receptor Complex
Jie Xu et al.
MOLECULAR ENDOCRINOLOGY (2011)
Dopamine Receptors in Human Adipocytes: Expression and Functions
Dana C. Borcherding et al.
PLOS ONE (2011)
C-MET as a new therapeutic target for the development of novel anticancer drugs
Israel Canadas et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2010)
Crystal Structure of an Affinity-matured Prolactin Complexed to Its Dimerized Receptor Reveals the Topology of Hormone Binding Site 2
Isabelle Broutin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Translating cancer research into targeted therapeutics
J. S. de Bono et al.
NATURE (2010)
Antibody-drug conjugates for cancer: poised to deliver?
Bethan Hughes
NATURE REVIEWS DRUG DISCOVERY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors
Vincent Rouet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Louis M. Weiner et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Biological Significance of Prolactin in Gynecologic Cancers
Vera V. Levina et al.
CANCER RESEARCH (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Activation of the unliganded estrogen receptor by prolactin in breast cancer cells
L. Gonzalez et al.
ONCOGENE (2009)
What can we learn from rodents about prolactin in humans?
Nira Ben-Jonathan et al.
ENDOCRINE REVIEWS (2008)
Human prolactin gene promoter regulation by estrogen:: Convergence with tumor necrosis factor-α signaling
A. D. Adamson et al.
ENDOCRINOLOGY (2008)
Drug therapy: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma
Bruce D. Cheson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells
Michele L. Scotti et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity
Sacha J. Howell et al.
BREAST CANCER RESEARCH (2008)
Structural and thermodynamic bases for the design of pure prolactin receptor antagonists
Jean-Baptiste Jomain et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
Andrew M. Scott et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Drug insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia?
Vincent Goffin et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2006)
Prolactin in man: a tale of two promoters
Sarah Gerlo et al.
BIOESSAYS (2006)
Development and potential clinical uses of human prolactin receptor antagonists
V Goffin et al.
ENDOCRINE REVIEWS (2005)
Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A
JF Langenheim et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Mechanism for ordered receptor binding by human prolactin
U Sivaprasad et al.
BIOCHEMISTRY (2004)
The N-terminus of human prolactin modulates its biological properties
S Bernichtein et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2003)
Development of pure prolactin receptor antagonists
S Bernichtein et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
New homologous bioassays for human lactogens show that agonism or antagonism of various analogs is a function of assay sensitivity
S Bernichtein et al.
ENDOCRINE (2003)
Prolactin as an autocrine/paracrine growth factor in human cancer
N Ben-Jonathan et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2002)
Clinical use a of growth hormone receptor antagonist in the treatment of acromegaly
WM Drake et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2001)
Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation
M Llovera et al.
ONCOGENE (2000)
Share Paper
